Clinical Scorecard: Surgical Sequencing in Esophageal Cancer
At a Glance
| Category | Detail |
|---|---|
| Condition | Locally advanced esophageal squamous cell carcinoma (ESCC) |
| Key Mechanisms | Neoadjuvant chemoradiotherapy (NCRT) vs. surgery followed by adjuvant therapy |
| Target Population | Patients aged 18 to 75 years with histologically confirmed locally advanced thoracic ESCC |
| Care Setting | Single-center trial at Sichuan Cancer Hospital, China |
Key Highlights
- 5-year overall survival was 59% for both NCRT and adjuvant therapy groups
- Patients achieving pathologic complete response (pCR) had 5-year overall survival of 77%
- NCRT resulted in lower rates of lymph node involvement and vascular invasion
- Safety outcomes were comparable, with mild to moderate adverse events
- Complete tumor resection with negative margins achieved in over 95% of patients
Guideline-Based Recommendations
Diagnosis
- Histologically confirm locally advanced thoracic ESCC
Management
- Consider NCRT for patients likely to achieve pCR; otherwise, surgery followed by adjuvant therapy is reasonable
Monitoring & Follow-up
- Follow-up for survival outcomes and disease-free survival post-treatment
Risks
- Higher rates of hematologic and gastrointestinal toxic effects with NCRT
Patient & Prescribing Data
Patients with locally advanced thoracic ESCC staged as cT1N+M0 or cT2–4aNxM0
Treatment strategies should consider likelihood of achieving pCR
Clinical Best Practices
- Utilize a multidisciplinary team for treatment planning
- Assess individual patient response to NCRT before recommending treatment approach
- Monitor for adverse events and manage them appropriately
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
